Drug updated on 12/11/2024
| Dosage Form | Cream (topical; 10 mg [1%]) |
| Drug Class | Quinolone antimicrobials |
| Ongoing and Completed Studies | ClinicalTrials.gov |
Indication
- Indicated for the topical treatment of impetigo due to Staphylococcus aureus Streptococcus pyogenes or in adult and pediatric patients 2 months of age and older.
Latest News
Summary
- This summary is based on the review of one systematic review/meta-analysis. [1]
- Ozenoxacin 1% cream demonstrated the strongest evidence of effectiveness for treating nonbullous impetigo in nonendemic settings, compared to other treatments such as retapamulin and a new minocycline formulation.
- In endemic settings where impetigo is more prevalent, oral co-trimoxazole and benzathine benzylpenicillin G injection were equally effective in treating severe cases of impetigo.
- No significant differences in effectiveness were noted for specific population types or subgroups based on the provided evidence.
- There is no safety information available in the reviewed studies.
Product Monograph / Prescribing Information
| Document Title | Year | Source |
|---|---|---|
| Xepi (ozenoxacin) Prescribing Information. | 2019 | Cutanea Life Sciences, Inc., Wayne, PA |
Systematic Reviews / Meta-Analyses
| Document Title | Year | Source |
|---|---|---|
| Emerging Treatment Strategies for Impetigo in Endemic and Nonendemic Settings: A Systematic Review | 2021 | Clinical Therapeutics |
Clinical Practice Guidelines
| Document Title | Year | Source |
|---|---|---|
| Pediatric impetigo: an expert panel opinion about its main controversies. | 2022 | Journal of Chemotherapy (Florence, Italy) |